Taiwan Liposome Company, Ltd. (TLC) |
| 7 0 (0%) 04-24 15:47 |
| Open: | 7 |
| High: | 7.09 |
| Low: | 7 |
| Volume: | 12,421 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 46.86 |
| Resistance 1: | 40.12 |
| Pivot price: | 38.22 |
| Support 1: | 37.71 |
| Support 2: | 36.22 |
| 52w High: | 7.7 |
| 52w Low: | 4.07 |
Financials
| EPS | 2.520 |
| Book Value | 22.170 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.839 |
| Profit Margin (%) | 45.79 |
| Operating Margin (%) | -8.93 |
| Return on Assets (ttm) | 2.4 |
| Return on Equity (ttm) | 11.2 |
Company news
Mon, 13 Jun 2022
TLC Announces TLC599 Agreement with Endo - Yahoo Finance
Mon, 13 Jun 2022
Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain - PR Newswire
Wed, 08 Sep 2021
TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares - Yahoo Finance
Mon, 05 Jul 2021
TLC Announces Details of Stock Swap Transactions - GlobeNewswire
Wed, 26 May 2021
Zydus and TLC sign agreement to market Liposomal Amphotericin B in India - Indian Pharma Post
Tue, 25 Jun 2019
TLC Announces Development and License Agreement with Birdie Biopharmaceuticals for NanoX™ Immunotherapy Product - BioSpace
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
